Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Notes Payables (2016 - 2020)

Altimmune (ALT) has disclosed Notes Payables for 7 consecutive years, with $632000.0 as the latest value for Q2 2020.

  • On a quarterly basis, Notes Payables rose 286.02% to $632000.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $632000.0, a 286.02% increase, with the full-year FY2018 number at $71596.0, up 44.05% from a year prior.
  • Notes Payables was $632000.0 for Q2 2020 at Altimmune, up from $105062.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.5 million in Q3 2018 to a low of $49702.0 in Q2 2017.
  • A 5-year average of $386259.6 and a median of $134393.0 in 2019 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: soared 2852.11% in 2018, then crashed 92.84% in 2019.
  • Altimmune's Notes Payables stood at $458629.0 in 2016, then tumbled by 89.16% to $49702.0 in 2017, then surged by 44.05% to $71596.0 in 2018, then surged by 46.74% to $105062.0 in 2019, then surged by 501.55% to $632000.0 in 2020.
  • Per Business Quant, the three most recent readings for ALT's Notes Payables are $632000.0 (Q2 2020), $105062.0 (Q3 2019), and $163724.0 (Q2 2019).